Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:13:12 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Spago Nanomedical Q3 2022 - Tumorad closing in on clinical development

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Spago Nanomedical Q3 2022 - Tumorad closing in on clinical development

2022-11-08 15:59:00

Redeye comments on Spago’s Q3 2022 report, and we estimate that the company is closing in on wrapping up its phase I SAGOPIX-01 trial with contrast agent SpagoPix (SN132D) and initiating a phase I/IIa trial with radionuclide drug candidate Tumorad (177Lu-SN201). We review our estimates and make some adjustments to our valuation.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.